Rexahn Pharmaceuticals Inc RNN:NYSE MKT LLC (Common Stock)
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 0.76 | 0.0023 0.30% | 1,023,768 | 1.7M |
Latest News Headlines for Rexahn Pharmaceuticals Inc
Rexahn Pharmaceuticals to Present at 13th Annual BIO Investor Forum ROCKVILLE, Md., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, PhD, the Company's Chief Executive Officer, will present at the 13(th) Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13(th) Annual BIO Investor Forum features leading private and emerging public companies. The presentation will be on Tuesday, October 7 at 10:30 am PDT. The presentation will be webcast live. To access the webcast, please visit http://www.veracast.com/webcasts/bio/investorforum2014/36105151112.cfm. The meeting will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.
Latest Annual and Quarterly SEC Filings
More FilingsCompany Background
Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company's pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company's drug candidate, Archexin is an anticancer Akt inhibitor.
collapse, right-facing arrow indicating collapsed view of sectionOverview
| Bid | Size | -- | -- |
|---|---|
| Ask | Size | -- | -- |
| Price Open | 0.769 |
| Previous Close | 0.76 |
| Day High | -- |
| Day Low | -- |
| 52 Week High | 1/13/2014 | 1.85 |
| 52 Week Low | 11/7/2013 | 0.37 |
| % Off 52 Week High | (58.92)% |
| % Off 52 Week Low | 105.41% |
| Beta (5 Yr) | 1.05 |
| Volatility Avg | 10/8/2014 | 106.85 |
| 10-Day Avg. Volume | 1,664,152 |
| Market data is delayed by at least 20 minutes. | |
collapse, right-facing arrow indicating collapsed view of sectionFundamentals
| EPS (TTM) | 6/30/2014 | (0.12) |
|---|---|
| P/E Ratio | 6/30/2014 | -- |
| Market Cap | Micro Cap | 135M |
| Shares Outstanding | 178.25M |
| Float | 155.4M |
collapse, right-facing arrow indicating collapsed view of sectionDividends
| Dividend Yield | -- |
|---|---|
| Ex-Date | -- |
| Dividend Announcement | -- |
| Date of Record | -- |
| Payable | -- - -- |
| Payable Date | -- |
Peers Information HelpRNN Rexahn Pharmaceuticals Inc vs. Peers
| Peers | |
|---|---|
RNN Rexahn Pharmaceuticals Inc | 49.02% |
Pfizer Inc. | -4.08% |
Eli Lilly and Co | 27.92% |
Bristol-Myers Squibb Co | -5.53% |
Keryx Biopharmaceuticals | 27.34% |
RNN Rexahn Pharmaceuticals Inc | 0.00% |
Pfizer Inc. | 3.54% |
Eli Lilly and Co | 3.00% |
Bristol-Myers Squibb Co | 2.87% |
Keryx Biopharmaceuticals | -- |
RNN Rexahn Pharmaceuticals Inc | 0.30% |
Pfizer Inc. | 2.05% |
Eli Lilly and Co | 1.59% |
Bristol-Myers Squibb Co | 0.88% |
Keryx Biopharmaceuticals | 5.17% |